JerMa88/BMC_Gastroenterology_Peer_Reviews huggingface dataset:
Review for 10.1186/s12876-024-03134-w (2024)

Title:  Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a
systematic review and meta-analysis
Version: 1 Date: 09 Oct 2023
Reviewer:  Tsunehiko Maruyama
Reviewer's report:
As the author has mentioned in his limitations, information on RAS and BRAF is considered
essential. In addition, the site of the primary tumor is also necessary information.
The comparison of BEV to placebo and BEV to CET and PAN makes the results unclear.
Review for 10.1186/s12876-024-03134-w (2024)

Title:  Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a
systematic review and meta-analysis
Version: 1 Date: 12 Nov 2023
Reviewer's report:
Dear Editor,
I appreciate the opportunity to review the manuscript titled "Effectiveness of Bevacizumab in the
Treatment of Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis" submitted
to BMC Gastroenterology. The authors have embarked on a commendable effort to conduct a
meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of bevacizumab
in treating metastatic colorectal cancer. However, there are several concerns, potentially impact
the integrity of the entire study
Introduction and Rationale: The introduction lacks a clear demonstration of the study's necessity.
While the authors briefly touch upon the significance of bevacizumab in colorectal cancer
treatment, they fall short in justifying the primary objective of the study – performing a
systematic review and meta-analysis of the Effectiveness of Bevacizumab in the Treatment
of Advanced Colorectal Cancer. It is crucial to explicitly state the rationale for this review,
especially given the existence of previous systematic reviews and meta-analyses on related
topics. Notably, the authors should clarify how their study contributes uniquely to the existing
body of knowledge in light of publications like:
- The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal
cancer: a systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/35750983/
- Chemotherapy plus panitumumab/cetuximab versus chemotherapy plus bevacizumab
in wild-type KRAS/RAS metastatic colorectal cancer: a meta-analysis. https://
pubmed.ncbi.nlm.nih.gov/36374121/
- Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab,
and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A
Systematic Review and Meta-Analysis. https://pubmed.ncbi.nlm.nih.gov/30499082/
- Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic
Colorectal Cancer: A Meta-analysis https://pubmed.ncbi.nlm.nih.gov/29323221/
- Anti#angiogenic therapies for metastatic colorectal cancer https://www.cochranelibrary.com/
cdsr/doi/10.1002/14651858.CD005392.pub3/full
- Second#line systemic therapy for metastatic colorectal cancer https://
www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006875.pub3/full
Database Selection and Bias: The authors systematically searched PubMed, Medline, and
Cochrane Library. However, it is crucial to note that PubMed is primarily a search engine for the
Medline bibliographic database. To ensure a comprehensive literature review, the authors should
include at least one additional database from the Embase or Scopus group. The manuscript
should explicitly acknowledge the limitation arising from the choice of databases, emphasizing
the potential bias introduced.
Best regards,
Review for 10.1186/s12876-024-03134-w (2024)

Title:  Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a
systematic review and meta-analysis
Version: 3 Date: 23 Dec 2023
Reviewer:  Tsunehiko Maruyama
Reviewer's report:
After all, the most significant disadvantage of this paper is the lack of information on RAS,
BRAF and tumor site. This absence reduces the quality of this review.
As far as comparing BEV to placebo and BEV to CET and PAN is concerned, this confusion
cannot be resolved and the value of the paper is diminished.
Review for 10.1186/s12876-024-03141-x (2024)

Title: Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN
diet-induced obese and biopsy-confirmed mouse model of NASH
Version: 1 Date: 06 Dec 2023
Reviewer's report:
The authors provided interesting findings on the beneficial effect of dietary intervention for
the amelioration of diet-induced NASH model. ALthough the results are interesting, several
experiments may be necessary to clearly strengthen their findings as shown below:
1. While the authors performed a few experiments with regard to hepatocellular senescence, p21
positive cell area and SASP would not be sufficient to fully address what the authors intended
to demonstrate in the title of rhis manuscript. At least b-galactosidase staining or other types of
senescence markers (e.g., Lamin B1, gammaH2AX, etc.) need to be further provided.
1-1. Although the authors performed RNA sequencing using livers obtained from experimental
mice, the authors may consider examining the protein expression of several key molecules so
as to fully validate their findings.
2. It is advised to present additional in vivo data in relation to glucose metabolism (e.g., plasma
glucose, plasma insulin, insulin sensitivity markers in representative organs), so the effect of
dietary intervention on NASH can be further demonstrated.
3. How the weight of adipose tissue was affected? Can this change be attributable to overall
reduction of body weight upon dietary intervention in those mice?
4. In order to prove subtle change of fibrosis markers upon dietary intervention, the authors may
perform additional experiments to analyze fibrotic changes, including hydroxyproline contents,
Masson's Trichrome staining, etc.
4-1. While the overall fibrosis score did not markedly change upon  8 or 16 weeks of dietary
intervention, alpha-SMA or Col1a1 positive area were significantly reduced. Any explain for
this discrepancy?
4-2. Can the authors examine whether the activity and/or the population of hepatic stellate cells
were markedly affected by dietary intervention?
Review for 10.1186/s12876-024-03141-x (2024)

Title: Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN
diet-induced obese and biopsy-confirmed mouse model of NASH
Version: 1 Date: 10 Dec 2023
Reviewer's report:
Felnsted-Jensen M. et al, have nicely described how dietary intervention reverses molecular
signatures of hepatocellular senescence in GAN diet-induced mouse model of NASH. Studies in
mice models that resemble human pathophysiology are essential to improve the understanding
of human NASH and pave the way for novel therapeutic approaches.
In order to accept the article some minor issues need to be fixed.
First, figures should be reorganized since the section “Dietary intervention improves hallmarks
of NASH and fibrosis in GAN DIO-NASH mice” results confusing and adds complexity to
the reader due to constant jumps from one figure to another, without respecting the established
order. Figures and graphs should be reorganized in order to fit with the text.
Second, regarding liver histology, pictures of vehicle 8w and 16w are missing. They should be
included to have the full image.
Third, showing all the groups (Chow vehicle, DIO-NASH vehicles-8w,16w,24w- and DIO-
NASH Chow-reversal-8w,16,24w) in the RNA-seq results is key to understand the changes.
Statistical significances also need to be shown. Fig 5B, Fig 6C-D and Fig 8B need to me
modified. Additionally, a vast amount of genes has been studied and the reader could benefit
from some guidance to understand their relevance. In this regard, the most relevant results could
be confirmed by qPCR or WB.
Review for 10.1186/s12876-024-03149-3 (2024)

Title: Identification of differentially methylated regions associated with both liver fibrosis and
hepatocellular carcinoma
Version: 0 Date: 21 Jun 2023
Reviewer's report:
In this manuscript the authors described identification of 17 differentially methylated regions
(DMRs) associated with liver fibrosis and hepatocellular carcinoma in humans by searching
different publicly available databases. They found 12 hypomethylated and 5 hypermethylated
DMRs in both cirrhosis and HCC, suggesting that aberrations in DNA methylations occurs
before HCC development.
o This study is based totally on database search. The authors did not validate DMR of any genes
in primary tumors or cirrhotic livers of human and/or animal origins.
• The authors did not provide any experimental evidence demonstrating that the differential
methylation of ELF1, NFIX, HDAC4, KAZN, TNNT3, and ALDH3B2 are causally linked to
fibrogenesis or hepatocarcinogenesis.
• It would be important also to determine whether there is any correlation between differential
methylation of the critical genes they identified with their transcript levels by searching publicly
available databases.
• Do any these genes are differentially methylated and/or expressed in any animal model of
fibrosis?
• It is not clear what the authors meant by “deteriorate” in this sentence “These genes could
deteriorate transcriptional regulation, alter the cytoskeleton, or decrease detoxification, resulting
in the development of liver fibrosis and consequent HCC (Fig. 5)”.
• Figure legends are too brief.
• In Fig. 5, significance of red and black fonts for different genes are not described. Also, the
pictures of the cirrhotic liver and HCC are blurry.
Review for 10.1186/s12876-024-03149-3 (2024)

Title: Identification of differentially methylated regions associated with both liver fibrosis and
hepatocellular carcinoma
Version: 0 Date: 04 Sep 2023
Reviewer:  Maarit Tiirikainen
Reviewer's report:
The authors provide a nice article on DMR analysis of GEO data sets produced from samples
with  liver cirrhosis and HCC of either viral or alcohol etiology.
This paper is continuation of the  same group's analysis of  DMRs in NAFLD and especially
fibrotic liver. The paper is of interest to the field and in general well-written. The only concern is
that when describing the results from the first GEO dataset, it is sometimes hard to follow which
etiology is in question for the cirrhosis and  HCC. I would sugget using a prefix to separate the
two etiologies, such as a-cirrhosis and v-cirrhosis.
Review for 10.1186/s12876-024-03149-3 (2024)

Title: Identification of differentially methylated regions associated with both liver fibrosis and
hepatocellular carcinoma
Version: 4 Date: 09 Jan 2024
Reviewer's report:
In the revised version the authors have provided additional data to strengthen the conclusions
of the manuscript. However, some of the results as presented in the abstract are not their own
data. For  example, the following sentences in the abstract
"These genes altered the epigenetic regulation in liver cells, leading to the development of HCC.
Knockdown of KAZN inhibits the differentiation and stimulates proliferation, suggesting that
the decreased expression of KAZN inhibits the differentiation and stimulates the proliferation
of liver cells, leading to the development of HCC." are  not based on their own data. Therefore,
these cannot be included in the results section without proper citation. Abstract should contain
only their findings based on their analysis.
Review for 10.1186/s12876-024-03144-8 (2024)

Title: Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of
liver cancer: a systematic review and single-arm meta-analysis
Version: 0 Date: 04 Dec 2023
Reviewer's report:
• The authors would better to specify the inclusion criteria for the studies selected in the meta-
analysis. Readers need to know the characteristics of the studies included to understand the
generalizability of your findings.
• The authors would better to provide more details about the MINORS tool used for evaluating
the quality of included studies. Specify the criteria assessed and mention any limitations of the
tool.
• Please clarify the statistical methods used in the meta-analysis. Explain any heterogeneity
among studies and how it was addressed.
• While the results are presented comprehensively, consider using a more structured format. For
example, create a table summarizing key findings such as ORR, DCR, mPFS, mOS, and adverse
events for easier reference.
• It's noted that the prevalence of adverse events is 87%, and the occurrence of grade 3 or higher
adverse events is 35%. However, the confidence intervals for these estimates seem unusual (95%
CI: 63%-102% and 95% CI: -1%-71%). Verify and correct if necessary.
• The authors should enhance the readability in language. For instance, "prevalence of adverse
events" might be better replaced with "incidence of adverse events."
• The conclusion mentions exercising vigilance concerning potential adverse reactions.
Elaborate on specific recommendations for clinical practice or further research based on your
findings.
• Check the spelling of "Carilizumab" in the keywords; it seems to be a typographical error and
should likely be "Camrelizumab."
Review for 10.1186/s12876-024-03144-8 (2024)

Title: Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of
liver cancer: a systematic review and single-arm meta-analysis
Version: 1 Date: 09 Jan 2024
Reviewer's report:
The manuscript has been quite improved.
As minor comment, I only suggest to expand the discussion about the strength and the limitations
of CARES trial in light of the considerations reported in the accompanying editorial (PMID:
36174622 )
Review for 10.1186/s12876-024-03139-5 (2024)

Title: Not All Carotenoids Can Reduce the Risk of Gastric Cancer: A Systematic Review with
Meta-Analysis
Version: 1 Date: 06 Sep 2023
Reviewer's report:
This manuscript entitled " Not All Carotenoids Can Reduce the Risk of Gastric Cancer: A
Systematic Review with Meta-Analysis" is of potential interest. However, it needs minor
modifications, which you must address in the text to accept in our journal.
1. You should check the whole text for plagiarism.
2. A native recommends English editing.
3. In the discussion section, you should clarify the exact mechanism of action of All Carotenoids
that can impact the risk of Gastric Cancer.
Review for 10.1186/s12876-024-03139-5 (2024)

Title: Not All Carotenoids Can Reduce the Risk of Gastric Cancer: A Systematic Review with
Meta-Analysis
Version: 1 Date: 30 Dec 2023
Reviewer's report:
The paper, entitled: Not All Carotenoids Can Reduce the Risk of Gastric Cancer: A Systematic
Review with Meta-Analysis  well written approximately, but it needs some major revision as
follow as:
Please Check.
-Abstract: The statistical model used and the name of the statistical package should be
mentioned.
-Methods: 2.1.2 Interventions  (I): The included studies were observational, so intervention has
no meaning. It is better to use exposure in parentheses according to PICOT's strategy
-2.1.3 Control (C): This part of PICOTS is also related to the control group (placebo or routine
treatment) in interventional studies (RCTs) and has no meaning in observational studies, and
this item should be removed too!
-The results of reporting bias (quality of studies) are not mentioned in the text.
-The general charachetertics s of the included studies  must be mentioned as a table. (name of
author, year of publication, place of publication, sample size, type of study, and quality of study)
and other necessary information.
-Figure 5: Why is the funnel plot only in the subtype of a carotenoid has been reported? It is better
to report this result by type of studies separately, just as you have separated the results according
to type of studies. In total, two graphs are enough. Funnel plot for case control and funnel plot
for cohort-studies. so, the results of this section are needed to be revised in the related text
Review for 10.1186/s12876-024-03139-5 (2024)

Title: Not All Carotenoids Can Reduce the Risk of Gastric Cancer: A Systematic Review with
Meta-Analysis
Version: 2 Date: 16 Jan 2024
Reviewer's report:
Subject: Acceptance of Manuscript for Publication
Dear Editor
I am writing to inform you that I have reviewed the revised version of the manuscript
titled :Not All Carotenoids Can Reduce the Risk of Gastric Cancer: A Systematic Review with
Meta-Analysis. After careful consideration of the comments and suggestions provided by the
reviewers, I am pleased to recommend the acceptance of the manuscript for publication in BMC
Gastroenterology
The authors have adequately addressed the concerns raised by the reviewers and have made
significant improvements to the manuscript.
Thank you for considering my assessment and recommendation. Please do not hesitate to contact
me if you require further information or clarification. I look forward to hearing about the final
decision regarding the acceptance of this manuscript.
Sincerely.
Review for 10.1186/s12876-024-03150-w (2024)

Title: Clinical Features and Fecal Microbiota Characteristics of Patients with Both Ulcerative
Colitis and Axial Spondyloarthritis
Version: 1 Date: 06 Dec 2023
Reviewer's report:
This was a well conducted study to analyse the fecal dysbiosis in patients with UC and axial
involvement. I just have two comments:
1. Paragraph 2 in Discussion section: It was written that risk factors for the development of
axial SpA was performed but, the results in Table 1 can at best be described as association of
clinical features in patients with or without axial SpA. This cannot be interpreted as risk factors
for developing axial involvement in UC patients. I suggest to delete this paragraph as this is also
not the ai of this study.
2. In the paragraph on limitations of the study, I am not able to understand the following sentence
"The results of this study are only indicative of the diagnosis and treatment of parenteral axSpA
in some patients with UC at our medical center." I suggest to rephrase this sentence so that
readers can understand what the authors meant.
3. Title of References is in Chinese script, please translate it to English.
Review for 10.1186/s12876-024-03150-w (2024)

Title: Clinical Features and Fecal Microbiota Characteristics of Patients with Both Ulcerative
Colitis and Axial Spondyloarthritis
Version: 1 Date: 14 Dec 2023
Reviewer's report:
This study examines ulcerative colitis (UC) patients with and without axial spondyloarthritis
(axSpA), revealing a correlation between elevated C-reactive protein (CRP) and axSpA.
Moreover, fecal microbiota analysis suggests potential associations between specific
biosynthetic and metabolic pathways and axSpA incidence, warranting further investigation for
therapeutic insights. The manuscript's structure and description are well-crafted; however, I have
a few comments and questions for the authors:
1. This study suggests a correlation between elevated CRP and axSpA. Considering CRP’s
known fluctuations tied to disease activity, the basis for asserting its correlation with axSpA
needs clarification. Additionally, in cases where patients underwent multiple CRP tests, the
selection criteria for analysis, such as which specific test, requires elucidation.
2. This study employed metabolic pathway analysis of fecal flora to explore the potential
pathogenesis of UC-axSpA. Nonetheless, the limited sample size underscores the need for an
additional patient cohort to validate these findings.
3. Fecal samples were obtained during hospitalization for UC flare-up, but the timing of
sample collection remains unspecified. It is crucial to clarify the timing of sample collection,
particularly considering the potential impact of medication, such as corticosteroids, and
intestinal inflammation on the fecal microbiota.
4. Escherichia_Shigella exhibited a positive association with axSpA incidence, while
Faecalibacterium showed a negative association. However, the conclusion erroneously suggests
both are associated with axSpA. A correction is needed to reflect their distinct association
accurately.
Review for 10.1186/s12876-023-03116-4 (2024)

Title: Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver
fibrosis
Version: 1 Date: 22 Sep 2023
Reviewer:  Jean-Pierre Zarski
Reviewer's report:
This study reports value suppression tumorigenicity soluble 2 as non-invasive marker in chronic
hepatite C, in comparison with scores Fibroscan, APRI and FIB-4. Unfortunately, only 164
patients were included, which is highly insufficient after eliminating many patients for whom we
have no comparative data. In addition, liver biopsy was not available as a marker for comparison.
Finally, the FIB-4 and the APRI are not the best markers of the fibrose (use the Fibrotest, the
Fibrometer or the Hepascore). Nor do we know the criteria for good-quality elastometry. Results
are not very good, particularly for the diagnosis of severe fibrosis (F3) or cirrhosis.
Review for 10.1186/s12876-023-03116-4 (2024)

Title: Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver
fibrosis
Version: 1 Date: 14 Oct 2023
Reviewer:  Hirotoshi Ebinuma
Reviewer's report:
Authors demonstrated the usefulness of a novel serum marker for liver fibrosis. The comparison
of the values of this marker before and after DAAs treatment for the patients of chronic hepatitis
C is a innovative and useful method, but it may need to be added or modified in the following
points.
Major points
1. This manuscript describe that sST2 is a useful single serum marker for assessing liver fibrosis.
However, it is already known that the existing single markers such as hyaluronic acid or type IV
collagen 7S are useful as single serum markers of liver fibrosis. The usefulness of sST2 should
be compared with these existing single serum markers.
2. Describe the significant differences in each graph in Figure 4. In Figure 4A, it appears that
the post-treatment sST2 values are predominantly lower than the pre-treatment values in some
fibrotic stages. If so, we cannot conclude that sST2 values do not affect by liver inflammation.
In addition, describe the significant differences in Table 2
3. How about comparing ROC curves of ST2 values for the assessment of liver fibrosis
separately before and after DAAs treatment?
Review for 10.1186/s12876-023-03116-4 (2024)

Title: Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver
fibrosis
Version: 2 Date: 11 Dec 2023
Reviewer:  Jean-Pierre Zarski
Reviewer's report:
The manuscript has taken into account the remarks of the 2 reviewers and has been modified
according to their recommendations. The discussion now seems a little long and can be slightly
reduced.
Review for 10.1186/s12876-023-03116-4 (2024)

Title: Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver
fibrosis
Version: 2 Date: 24 Dec 2023
Reviewer:  Hirotoshi Ebinuma
Reviewer's report:
This resubmitted  manuscript is  commendable in that authors adequately answer against the
reviewers' questions, but unfortunately does not provide any new findings.
The finding that soluble suppression of tumorigenicity 2 may be utilized as a new marker of
liver fibrosis is appreciated, so this manuscript is worthwhile to accept to publish, although the
number of cases is small and liver biopsy was not performed.
Review for 10.1186/s12876-024-03145-7 (2024)

Title: Early encapsulation of peripancreatic fluid/necrosis collections on imaging (CECT) in
acute pancreatitis: influential factors and clinical significance for prognosis
Version: 3 Date: 21 Jan 2024
Reviewer:  Marianna Arvanitakis
Reviewer's report:
The comments have been addressed adequately and the manuscript has been significantly
improved.
Review for 10.1186/s12876-024-03140-y (2024)

Title: Clinical factors associated with stable treatment of chronic constipation in Japanese
patients
Version: 1 Date: 10 Oct 2023
Reviewer's report:
This is a retrospective, cross-sectional, multicenter study. Patients with chronic constipation
(CC) were devided in two groups according to stable CC treatment (up to two prescription
modification over one year) or unstable (three or more prescription changes for CC). The patients
were followed for at least one and a half years. The authors   identify that proton pump use was
significantly related to the stable CC groups with OR  2.81 (1.12-7).
However this correlation could be byased by the limited number of patients (114)  and their
different distribution of them (n=82 for stable group and 32 for unstable one).
Furthermore, the authors do not mention the kind of drug forCC in each group of patients.,
neither the kind of PPI.
Review for 10.1186/s12876-024-03140-y (2024)

Title: Clinical factors associated with stable treatment of chronic constipation in Japanese
patients
Version: 1 Date: 04 Nov 2023
Reviewer's report:
Dear Authors,
Thanks for preparing these study. I read the manuscript , and I found some point that not
reasonable including:
1- Would you please inform me about a citation for definition of the patients under the stable
versus unstable CC treatment.
2-Majority of the patients were in the geriatric group with some comorbidity, did you considered
this confounding factors? Because the gut flora is so different in this age group.
3- Table of baseline clinical data-1  shows that 12 stable CC treatment patients received 3 or
more types of laxative. This is not matched with the definition?
4- At discussion; you concluded that usage of acid suppressing agents could preserve stability
in treatment. Which acid lowering agent? How long a patient has taken that? Would you please
explain about that, because we know that acid lowering agents should be prescribed short time
in the FD /GERD  relief.
5- Would you please updated the references.
Finally, I think the manuscript need major revision, if possible.
Review for 10.1186/s12876-024-03140-y (2024)

Title: Clinical factors associated with stable treatment of chronic constipation in Japanese
patients
Version: 3 Date: 26 Nov 2023
Reviewer's report:
Dear authors, the title of study is novel and practical. Thanks for your complete explanations in
the text. However, the conclusion beside the result of  data analysis need to review and completed
regarding these points:
1- Please replace the word "relationship" instead of the word "correlation".
2- Please explain how acid suppressing drugs could reduce stress level?
3- The readers can not find " how many of your patients had functional dyspepsia, GERD, and
overlap of FD with GERD. Please consider the recorded data, what is the indication for prolong
consumption of acid lowering agents in your participants?
4-Please clarify about why you mentioned a general term of  acid lowering agent in your study;
e.g., based on small sample  size you can not address the type of acid lowering agent(PPI,
H2RB, ...)
5- Please include or exclude other confounding factors such as any antibiotic and/or probiotic/
any other supplements, smoking, and alcohol consumption in your study.
Review for 10.1186/s12876-024-03125-x (2024)

Title: The impact of endoscopist performance and patient factors on distal adenoma detection
and colorectal cancer incidence.
Version: 1 Date: 17 Oct 2023
Reviewer's report:
This is a high-quality study, but there are several problems:
1. Should positive results from repeated FS be included? Multiple FS examinations could reduce
the miss rate of adenomas, which may be the reason for the high ADR of distal colon with poor
bowel preparation compared with excellent.
2. The amount of time it takes to deal with the polyp during insertion or withdrawal may need to
be excluded. Negative FS examinations have no polyps to operate, so the insertion or withdrawal
time will be shorter, which may be the reason for the high detection rate of distal colorectal
adenoma of longer insertion or withdrawal time.
3. The end point of FS examination is not fixed, and the study concluded that the further the
segment is inserted, the detection of adenoma will also improve. However, the extension of the
insertion distance means that the insertion time and the withdrawal time will also be extended,
which may be another factor affecting the high detection rate of distal colorectal adenoma of
longer insertion or withdrawal time.
Review for 10.1186/s12876-024-03125-x (2024)

Title: The impact of endoscopist performance and patient factors on distal adenoma detection
and colorectal cancer incidence.
Version: 1 Date: 04 Dec 2023
Reviewer's report:
In this study, authors assessed the impact of endoscopists’ performance and patient factors
on distal adenoma detection and colorectal cancer incidence. A large number of patients were
registered in this trial and more than 34,000 participants received flexible sigmoidoscopy
screening in the 13 centres. Median follow-up was 17 years. After a detailed statistical analysis,
they found that bowel preparation quality and longer insertion and withdrawal time were key
for improving distal adenoma detection. Additionally, it was indicated that higher ADRs were
associated with a lower risk of distal CRC. The main research findings of this paper will be
important for prediction and prevention of distal CRC. I have no practical criticisms in terms
of methods, results and interpretation.
Review for 10.1186/s12876-024-03125-x (2024)

Title: The impact of endoscopist performance and patient factors on distal adenoma detection
and colorectal cancer incidence.
Version: 2 Date: 20 Dec 2023
Reviewer's report:
In this clinicopathological study, authors assessed the impact of endoscopists’ performance
and patient factors on distal adenoma detection and colorectal cancer incidence. A large
number of patients were registered in this trial and more than 34,000 participants received
flexible sigmoidoscopy screening in the 13 centres. Median follow-up was 17 years. After a
detailed statistical analysis, they found that bowel preparation quality and longer insertion and
withdrawal time were key for improving distal adenoma detection. Additionally, it was indicated
that higher ADRs were associated with a lower risk of distal CRC. The main research findings
of this paper will be important for prediction and prevention of distal CRC. I have no practical
criticisms in terms of methods, results and interpretation.
Review for 10.1186/s12876-024-03138-6 (2024)

Title: Evaluating the usefulness of considering the size and morphological type of type B2 vessel
area based on Japan Esophageal Society Classification in estimating tumor invasion depth in
superficial esophageal squamous cell carcinomas: study protocol for a prospective observational
study (Japan BEES study)
Version: 0 Date: 07 Oct 2023
Reviewer's report:
This is a manuscript concerning the protocol to examine whether the extent of B2 vessels
observed by magnifying endoscopy is useful for the diagnosis of invasion depth (MM/SM1).
This is a multicenter study conducted by representative Japanese endoscopists, and reviewer
believe that reliable data will be obtained.
It is stated that 4mm and 10mm are measured using endoscopic instruments, but details of what
kind of instruments are used for the measurement should be described.
We would also like to know whether the reliability of the measured data will be confirmed by
the Central Committee.
Review for 10.1186/s12876-024-03138-6 (2024)

Title: Evaluating the usefulness of considering the size and morphological type of type B2 vessel
area based on Japan Esophageal Society Classification in estimating tumor invasion depth in
superficial esophageal squamous cell carcinomas: study protocol for a prospective observational
study (Japan BEES study)
Version: 0 Date: 09 Oct 2023
Reviewer's report:
Thank you for inviting me to review the article entitled "Evaluating the usefulness of considering
the size and morphological type of type B2 vessel area based on Japan Esophageal Society
Classification in estimating tumor invasion depth in superficial esophageal squamous cell
carcinomas: study protocol for a prospective observational study (Japan BEES study)". The
authors presented the protocol details, however the trial lacking clinical significance for reasons
as follows:
a.  Even though the accuracy could be improved through this trial, it is  possible that patients
with low risks still require ESD to confirm the diagnosis.  For B2 type vessels, diagnostic ESD
should be recommended and is feasible in most hospitals .
b.  EUS and EUS following endoscopic sub-mucosal  saline injection are more obvious, and
could help to well distinguish most cases suitable for ESD rather than esophagectomy. In
addition, combining use of endoscopic ultrasound  may help increase the diagnostic yield of
this trial.
Review for 10.1186/s12876-024-03138-6 (2024)

Title: Evaluating the usefulness of considering the size and morphological type of type B2 vessel
area based on Japan Esophageal Society Classification in estimating tumor invasion depth in
superficial esophageal squamous cell carcinomas: study protocol for a prospective observational
study (Japan BEES study)
Version: 1 Date: 06 Jan 2024
Reviewer's report:
Now, I agree to acept.
I expect good results will be shown from this study.
Review for 10.1186/s12876-024-03138-6 (2024)

Title: Evaluating the usefulness of considering the size and morphological type of type B2 vessel
area based on Japan Esophageal Society Classification in estimating tumor invasion depth in
superficial esophageal squamous cell carcinomas: study protocol for a prospective observational
study (Japan BEES study)
Version: 1 Date: 15 Jan 2024
Reviewer's report:
"PEER REVIEWER ASSESSMENTS:
OBJECTIVE - Full research articles: is there a clear objective that addresses one or several
testable research questions? (Brief or other article types: is there a clear objective?)
Yes - there is a clear objective
DESIGN - Is the current approach (including controls and analysis protocols) appropriate for
the objective?
Yes - the approach is appropriate
EXECUTION - Are the experiments and analyses performed with sufficient technical rigor to
allow confidence in the results?
Yes - experiments and analyses were performed appropriately
STATISTICS - Is the use of statistics in the manuscript appropriate?
Yes - appropriate statistical analyses have been used in the study
INTERPRETATION - Is the current interpretation/discussion of the results reasonable and not
overstated?
Yes - the author's interpretation is reasonable
OVERALL MANUSCRIPT POTENTIAL - Has the author addressed your concerns sufficiently
for you to now recommend the work as a technically sound contribution? If not, can further
revisions be made to make the work technically sound?
Yes - current version is technically sound
PEER REVIEWER COMMENTS:
GENERAL COMMENTS: Dear authors
Thank you for your improvements.
This is a very interesting study and the protocol is very well described."
Review for 10.1186/s12876-024-03132-y (2024)

Title: Simultaneous detection of Helicobacter pylori infection comparing between white light
and image-enhanced endoscopy
Version: 1 Date: 13 Oct 2023
Reviewer:  Jun-Hyung Cho
Reviewer's report:
The major concerns about this manuscript are as below;
First, the similar reports were previously published in many countries. As the authors known,
RAC is reported to be a major finding of H. pylori negativity. Although several IEE were used,
the results from this study seem not to have a high priority.
Second, the criteria for H. pylori gastritis should be clearly defined in the method section. The
Kyoto classification and BLI/LCI findings, the known endoscopic findings, are not needed to
be written in the method section. They can be cited as references.
Third, Figure 3 shows the different distance between WLI/LCI and BLI/NBI. In contrast to
the close-up photos by BLI/NBI, the endoscopic features by WLI/LCI were seen as gross
appearance.
Fourth, the results using WLI and IEE were not shown in same Table. If the authors wish to
compare them as the manuscript title, they should be combined as same Table.
Fifth, the patients were divided by H. pylori infection status in Table 1, which was not required.
Other endoscopic findings including peptic ulcer, gastric atrophy, and intestinal metaplasia are
needed in Table 1.
Sixth, review of other studies including Table 4 and 5 are not needed as the form of original
research.
Seventh, the numbers of biopsy were not consistent in the abstract (five) and text body (four).
The area of biopsy should be described in detail according to RUT, histology, and culture.
Lastly, the number of IRB and registration number (eg. ClinicalTrials.gov) is required in the
section of study design.
Review for 10.1186/s12876-024-03132-y (2024)

Title: Simultaneous detection of Helicobacter pylori infection comparing between white light
and image-enhanced endoscopy
Version: 2 Date: 03 Jan 2024
Reviewer:  Masao Kobayakawa
Reviewer's report:
1. To prevent misunderstanding or confusion, the followings are recommended.
1) In the manuscript and Table 3 and Figure3, “magnifying NBI” or “magnifying BLI”, instead
of NBI or BLI, should be described as endoscopic diagnostic method of H. pylori infection using
magnifying method.
2) In the manuscript and Table 3, “Comprehensive findings on LCI” and “Comprehensive
findings on WLI” should be described as endoscopic diagnostic method of H. pylori infection
based on the presence of at least 1 of 8 findings according to Kyoto classification. Furthermore,
this explanation should be shown in the annotation of Table 3.
3)  Each finding indicative or non-indicative H. pylori infection should be described as XXX on
XXX, for example, diffuse redness on LCI or each finding on WLI.
2. Only sensitivity of the finding on magnifying BLI was significantly higher than that of
comprehensive findings on WLI, so that it is inappropriate to say that IEE significantly improved
real-time endoscopic diagnosis of H. pylori infection compared with WLI in the conclusions
of the Abstract and the Manuscript. Instead, precisely based on the result, the authors should
conclude that the sensitivity of enlarged or elongated pits with obscure SECNs or dense fine
irregular vessels on magnifying BLI was significantly higher for H. pylori infection status
compared with comprehensive findings on WLI.
Review for 10.1186/s12876-023-03099-2 (2024)

Title: Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C
and their risk of hepatocellular carcinoma in Hong Kong
Version: 3 Date: 11 Nov 2023
Reviewer's report:
1. In the abstract,  The conclusion should be revised. This article not just discussed  the recurrence
of HCC, but also the HCC incidence.
2. The introduction should be concise and clear.
3. Figure 5-7 should be merged into 1 figure.
4. And due to the limited data, the conclusion should made carefully.
Review for 10.1186/s12876-023-03099-2 (2024)

Title: Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C
and their risk of hepatocellular carcinoma in Hong Kong
Version: 3 Date: 13 Nov 2023
Reviewer's report:
This study on the treatment of patients with HCV has certain clinical value.
I have the following suggestions and questions.
1#While direct antivirals have been widely used to treat patients with HCV infection, they have
been shown to reduce all-cause mortality. However, the results are affected by many factors, so
it is necessary to study the influence of single factors in the later stage. For example: age, sex,
body mass index, geographical origin, route of infection, fibrosis score, alcohol consumption,
diabetes, etc. For follow-up studies, I recommend focusing on assessing how diabetes, weight
change, and alcohol consumption affect liver cancer risk, and extending follow-up, preferably
to more than seven years. Do you have any follow-up plans?
2#The follow-up time was insufficient. Although HCC risk decreased after a sustained
virological response to direct-acting antivirals, follow-up was not long enough to determine
whether cancer risk continued to decline to a level sufficient to forgo screening. Although the
authors also stated in the limitations, I recommend extending the follow-up time. The current
results are acceptable, will you continue to follow up in the later study?
3#METHODS---“Definitions”
“The diagnosis of cirrhosis would be established if at least one of the following was present:
i) liver histology showing stage 4 fibrosis (METAVIR score); ii) liver stiffness measurement
(LSM) greater than 12.5 kPa at transient elastography (FibroScan, Echosens, Paris, France) (33);
iii) signs of cirrhosis on imaging of the abdomen (34); iv) evidence of portal hypertension at
Oesophago-gastro-duodenoscopy (OGD).”
i, ii, iv can be determined. But number two: "liver stiffness measurement (LSM) greater than
12.5 kPa at transient elastography", LSM is a relatively new non-invasive quantitative evaluation
method of liver stiffness. But the latest is the SWE liver elasticity measure. There is still some
controversy about the repeatability and accuracy of the two ultrasound methods. If the authors
are to consider LSM as one of the diagnostic methods, it is necessary to add references to LSM
to support the article.Suggest added relevant references about the LSM.
Review for 10.1186/s12876-023-03099-2 (2024)

Title: Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C
and their risk of hepatocellular carcinoma in Hong Kong
Version: 7 Date: 12 Dec 2023
Reviewer's report:
The authors have answered all the questions. The study has certain clinical value. Looking
forward to follow-up studies.
Review for 10.1186/s12876-024-03124-y (2024)

Title: Symptom effects and central mechanism of acupuncture in patients with functional
gastrointestinal disorders: A systematic review based on fMRI Studies
Version: 1 Date: 26 Sep 2023
Reviewer's report:
This study on gastrointestinal symptoms and the mechanisms of acupuncture in FGID patients
is both intriguing and well-structured, offering valuable insights to its readers. However, there
are some noteworthy points to address before publication:
1. Kindly specify the databases utilized (e.g., Pubmed) in the abstract.
2. Please provide more comprehensive details regarding the inclusion and exclusion criteria
within the abstract.
3. The statement "Combined results showed that acupuncture could significantly improve the
clinical symptoms of FGIDs patients" requires clarification. What exactly does "combined
results" entail, and how do these results indicate the significant improvement in clinical
symptoms?
4. The conclusion in the abstract should be substantiated with evidence from the study's results.
5. On PROSPERO, the 'stage of review' is currently listed as 'review ongoing.' It would be more
accurate to update this to 'completed.'
6. Please include a description of the meta-analysis methods in the Methods section.
7. It would be beneficial to elucidate the rationale behind the inclusion of transcutaneous
electrostimulation in the study. Is it comparable to manual acupuncture (MA) and
electroacupuncture (EA) in terms of effects and central mechanisms?
8. Could you provide the rationale for incorporating anxiety and depression scores as secondary
outcomes in the study?
9. I recommend converting Table 3 into a figure to enhance data visualization.
10. Consider combining Figure 4 and Figure 5 into a single figure if Figure 5, which appears
less related to the study, is to be retained.
Your efforts in addressing these points will further enhance the clarity and quality of your
manuscript.
Review for 10.1186/s12876-024-03124-y (2024)

Title: Symptom effects and central mechanism of acupuncture in patients with functional
gastrointestinal disorders: A systematic review based on fMRI Studies
Version: 1 Date: 16 Oct 2023
Reviewer's report:
This study presents a systematic review of the effects and mechanisms of acupuncture
in the treatment of Functional Gastrointestinal Disorders (FGIDs). Notably, the skin and
central nervous system share a common embryological origin, the ectoderm, which gives
rise to cutaneous visceral reflexes that support the aforementioned investigations. This
observation helps explain, in a natural and comprehensive manner, the significant influence
of acupuncture and moxibustion treatments on various pathological processes, leading to
homeostatic regulation.
Some items may be discussed, including the spontaneous remission of symptoms and potential
placebo effects of acupuncture that should not be excluded. Moreover, the implications of
chronic pain on synaptic plasticity and changes in the CNS and various neural areas that
modulate pain should be considered.
Although the results suggest a benefit of acupuncture, the authors must clarify that there
are insufficient data to recommend the method as a first-line treatment. Moreover, there are
insufficient data to determine the long-term results.
A final open question that requires clarification is whether these procedures are effective only
for symptom relief or their underlying causes. The conclusion should be extended and novel
findings on acupuncture and the regulation of gastrointestinal function should be discussed.
Thank you.
Review for 10.1186/s12876-024-03136-8 (2024)

Title: A Review of 17 Cases of Mesenteric Panniculitis in Zhengzhou Ninth People's Hospital
in China
Version: 3 Date: 06 Oct 2023
Reviewer:  Eli D. Ehrenpreis
Reviewer's report:
Hello
This manuscript works well. Mesenteric panniculitis is an uncommon condition.
The following is suggested.
1. Change the title. It should be more specific, such as "A Review of ...Cases of Mesenteric
Panniculitis in a ...(Community or Academic)Hospital in ..(Rural or Urban) China.
2. "9 outpatients and 8 hospital patients were admitted by searching the electronic medical record
system using the term ‘‘MP’’. Should say "Seventeen cases of MP were identified using the
search terms (was the term really MP?). How were the searches performed? Was it on the emr?
What is the method used to conduct the search?
3.  How was the CT analysis performed? Are you just reporting what was on the report, or did
an independent radiologist review the images? If so, was he listed as an author? If so, give his
initials when describing this in the methods.
4. "MP is usually incidentally found during abdominal CT scans for other reasons based on
typical radiological features". This needs a better explanation. Are you saying that it is an
incidental finding? Aren't many patients getting an abdominal CT because of symptoms? Maybe
better to say that "MP is usually an incidental finding in patients undergoing abdominal imaging.
5. "For the MP, there is no consensus about the treatment, and the purpose is to reduce the
symptomatology. " No consensus by whom? Does this mean no guidelines? Several studies are
retrospective based on "how we do it", such as those by Mayo Clinic.
6. Based on the above "Although there is no standard treatment, prednisone seems to be an
effective treatment", this makes no sense. Are you stating that based on your experience,
prednisone appears to be effective?
There are grammatical and sentence structure issues in the manuscript. Editing by an English
speaker is suggested.